Microbot Medical (MBOT) Common Equity (2010 - 2026)

Microbot Medical's Common Equity history runs 17 years deep, the most recent figure standing at $74.1 million for Q1 2026.

• Quarterly Common Equity rose 155.97% year-over-year to $74.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.1 million (up 155.97% YoY) and the FY2025 annual result came in at $77.6 million, up 2097.0% from the prior year.
• Common Equity was $74.1 million for Q1 2026 at Microbot Medical, down from $77.6 million in the prior quarter.
• Across five years, Common Equity topped out at $78.2 million in Q3 2025 and bottomed at $3.5 million in Q4 2024.
• A 5-year average of $21.6 million and a median of $7.4 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity sank 69.04% — and 2025, when it surged 2097.0%.
• Microbot Medical's Common Equity stood at $7.3 million in 2022, then slumped by 38.25% to $4.5 million in 2023, then decreased by 21.57% to $3.5 million in 2024, then jumped by 2097.0% to $77.6 million in 2025, then retreated by 4.45% to $74.1 million in 2026.
• Business Quant data shows MBOT's Common Equity at $74.1 million in Q1 2026, $77.6 million in Q4 2025, and $78.2 million in Q3 2025.